129
Participants
Start Date
September 1, 2025
Primary Completion Date
September 1, 2028
Study Completion Date
March 1, 2030
Standard of Care Chemotherapy
Study treatment in the arm A is left to the investigator appreciations. This may include immune checkpoint inhibitors, docetaxel, topotecan for primary lung tumors, and FOLFOX, FOLFIRI or alkylating-based chemotherapy in primary digestive tumors.
Tarlatamab
Tarlatamab 10 mg every 2 weeks
Angers - CHU, Angers
Avignon - CH, Avignon
Besançon - CHU, Besançon
Boulogne - Ambroise Paré, Boulogne
Caen - CHU, Caen
Caen - CHU, Caen
Tours - CHU, Chambray-lès-Tours
Dijon - Centre Georges-François Leclerc, Dijon
Dijon - CHU Bocage, Dijon
Grenoble - CHU, Grenoble
Le Mans - CHG, Le Mans
Lille - Centre Oscar Lambret, Lille
Limoges - CHU, Limoges
Limoges - CHU, Limoges
Lyon - Centre Léon Bérard, Lyon
Lyon - Hôpital Edouard Herriot, Lyon
Lyon - Hôpital Privé Jean Mermoz, Lyon
Marseille - APHM, Marseille
Marseille - Institut Paoli-Calmettes, Marseille
Montpellier - CHU, Montpellier
Nice - Centre Antoine Lacassagne, Nice
Paris - Curie, Paris
Paris - Hôpital Cochin, Paris
Paris - Saint-Antoine, Paris
Paris - Tenon, Paris
Bordeaux - CHU, Pessac
Bordeaux - CHU, Pessac
Lyon - HCL, Pierre-Bénite
Poitiers - CHU, Poitiers
Reims - CHU, Reims
Rennes - CHU, Rennes
Rouen - CHU, Rouen
Nantes - Hôpital Laennec, Saint-Herblain
Nantes - Institut de Cancérologie de l'Ouest, Saint-Herblain
Strasbourg - Nouvel Hôpital Civil, Strasbourg
Toulon - CHI, Toulon
Toulouse - CHU, Toulouse
Tours - CHU, Tours
Vandoeuvre-lès-Nancy - Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
Villefranche sur Saône - CH, Villefranche-sur-Saône
Intergroupe Francophone de Cancerologie Thoracique
OTHER